Evidence map›Paper›PMID 40619537›Full record

ArticleEJNMMI research2025

Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia.

Moritz B Bastian, Tilman Speicher, Arne Blickle, Caroline Burgard, Julius L D Bastian, Mark Bartholomä, Andrea Schaefer-Schuler, Stephan Maus, Samer Ezziddin, Florian Rosar

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04833517 (REALITY Study), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04833517 unknown statusnot on this map

REALITY Study: Analysis of a Prospective REgistry to Assess Outcome and Toxicity of Targeted RadionucLide TherapY in Patients With mCRPC in Clinical Routine.

Typeobservational_patient_registrySponsorUniversität des SaarlandesRan2016 to 2025Enrolled500ConditionsProstate Cancer Metastatic, Castration Resistant Prostatic Cancer, Advanced Prostate Carcinoma
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Moritz B BastianDepartment of Nuclear Medicine, Saarland University, Kirrberger Str., Geb. 50, 66421, Homburg, Germany. moritz.bastian@uks.eu.ORCID http://orcid.org/0009-0008-2106-9548
Tilman SpeicherDepartment of Nuclear Medicine, Saarland University, Kirrberger Str., Geb. 50, 66421, Homburg, Germany.
Arne BlickleDepartment of Nuclear Medicine, Saarland University, Kirrberger Str., Geb. 50, 66421, Homburg, Germany.
Caroline BurgardDepartment of Nuclear Medicine, Saarland University, Kirrberger Str., Geb. 50, 66421, Homburg, Germany.
Julius L D BastianDepartment of Urology, Saarland University, Homburg, Germany.
Mark BartholomäDepartment of Nuclear Medicine, Saarland University, Kirrberger Str., Geb. 50, 66421, Homburg, Germany.
Andrea Schaefer-SchulerDepartment of Nuclear Medicine, Saarland University, Kirrberger Str., Geb. 50, 66421, Homburg, Germany.
Stephan MausDepartment of Nuclear Medicine, Saarland University, Kirrberger Str., Geb. 50, 66421, Homburg, Germany.
Samer EzziddinDepartment of Nuclear Medicine, Saarland University, Kirrberger Str., Geb. 50, 66421, Homburg, Germany.
Florian RosarDepartment of Nuclear Medicine, Saarland University, Kirrberger Str., Geb. 50, 66421, Homburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAim of this study was to analyze the safety of prostate-specific membrane antigen radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC) with preexisting mild to moderate leukopenia (CTCAE ≥ 1).

resultsThirty-seven mCRPC patients with preexisting leukopenia (leukocyte count < 3.8 × 10

conclusionAlthough marked preexisting leukopenia is often considered a relative contraindication for PSMA-RLT, our findings indicate that PSMA-RLT is feasible in patients with leukopenia of CTCAE grade ≥ 1. In our cohort, leukocyte counts remained stable without significant RLT-induced deterioration. Therefore, patients with leukopenia should not be categorically excluded from receiving PSMA-RLT.

trial registrationClinicaltrials.gov identifier: NCT04833517, registered 01.01.2016.

Indexed as

LeukopeniamCRPCPSMARadioligand therapyRLTSafety

Identifiers

PMID40619537
PMCPMC12229971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.